查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085946

肝病治療市場：2026-2032年全球市場預測（依疾病類型、治療類型、給藥途徑、藥物類別、最終用戶和分銷管道分類）

Liver Diseases Therapeutics Market by Disease Type, Therapy Type, Route Of Administration, Drug Class, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肝病治療市場將成長至 356.3 億美元，複合年成長率為 8.39%。

主要市場統計數據
基準年 2025 202.6億美元
預計年份：2026年 218.9億美元
預測年份：2032年 356.3億美元
複合年成長率 (%) 8.39%

肝病治療正從症狀管理轉向疾病改善、早期介入和精準醫療，涵蓋病毒性肝炎、代謝功能障礙相關性脂肪肝（MASLD）、自體免疫功能障礙相關性脂肪性肝炎（MASH）、自體免疫性肝病、膽汁淤積性緩解疾病、早期療育和肝細胞癌等疾病。由於肝病仍然是全球重要的健康負擔，因此該領域的市場機會巨大。根據世界衛生組織統計，2022年，全球有3.04億人患有慢性B型或C型肝炎，同年約有130萬人死於病毒性肝炎。

此外，由於肥胖、第二型糖尿病、酒精性肝病盛行率不斷上升以及人口老化，市場需求格局正在改變。據估計，全球約有三分之一的成年人患有代謝相關肝病（MASLD），這使得該患者群體可能需要無創診斷、心血管代謝疾病的綜合管理、抗纖維化治療以及長期監測。對於行業領導者而言，未來的發展取決於循證醫學支持的研發管線、為保險公司準備的療效數據、高度可擴展的診斷技術以及連接肝病學、腫瘤學、內分泌學、基層醫療和數位醫療的綜合護理模式。

治療環境的變革性變化

在肝病治療領域，隨著治療創新不再侷限於抗病毒藥物，而是擴展到代謝、免疫、纖維化和腫瘤機制等領域，肝病治療正經歷結構性轉變。直接抗病毒藥物（DAAs）徹底改變了C型肝炎的治療，在適當的患者中，治療率通常超過95%。同時，B型肝炎的長期治療策略也越來越重視功能性治療方法，包括免疫調節劑、RNA標靶療法和聯合治療。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過改善風險分層、臨床試驗設計、影像學和疾病監測，對肝病整體治療產生累積影響。利用 AI 分析超音波、CT、MRI、彈性成像、病理樣本、實驗室數據和電子健康記錄，可以比傳統流程更早識別出存在進行性纖維化、補償肝硬化或漏診肝細胞癌風險的患者。

關鍵區域洞察

亞太地區是肝病治療市場的重要區域，這主要歸因於該地區乙型肝炎的高發生率、糖尿病和肥胖症盛行率的不斷上升，以及中國、日本、韓國、澳洲、印度和東協市場對先進診斷技術的日益普及。市場成長與各國開展的肝炎根除計畫、擴大肝癌監測範圍、推廣非侵入性纖維化檢測、提升本地臨床實驗室能力密切相關。

關鍵群體特定見解

鑑於東南亞地區都市化加快和糖尿病盛行率上升，東協市場對於擴大B型肝炎防治、根除丙型肝炎以及代謝性肝病篩檢至關重要。海灣合作理事會（GCC）成員國雖然肥胖、第2型糖尿病和代謝相關肝病（MASLD）的盛行率較高，但隨著其醫療體系加大對專科護理、數位醫療、預防性篩檢和慢性病管理計畫的投入，這些地區正逐漸成為重點治療區域。

主要國家概況

美國在新型MASH治療、肝細胞癌創新、肝臟移植和高價值專科醫療方面處於主導，而加拿大則專注於實證醫學的普及、公共衛生篩檢和綜合肝炎管理。墨西哥和巴西正面臨MASLD和糖尿病相關肝病日益加重的負擔，因此對價格合理的診斷、抗病毒藥物的可及性、肝病學出版網路和肝硬化診療路徑的需求日益成長。

為行業領導者提供的實用建議

產業領導者應優先考慮那些能夠展現可衡量臨床價值的療法，例如逆轉纖維化、抑制肝硬化進展、降低補償風險、提高肝癌存活率以及提升以患者為中心的生活品質 (QOL)。在 MASH 中，成功的關鍵在於將藥物治療與非侵入性檢測、心臟代謝管理、生活方式支持以及清晰的基層醫療和肝病專科治療流程相結合。

調查方法

本執行摘要基於資訊來源檢驗、開發平臺負擔指標和醫療服務模式。

結論

在抗病毒藥物、代謝療法、抗纖維化藥物、免疫腫瘤學、診斷和人工智慧等技術的融合推動下，肝病治療正朝著更一體化和創新​​主導的方向發展。最大的機會可能來自於早期識別高風險患者、提高治療依從性、有效監測以及開發不僅能改變生物標記物，還能帶來持續臨床療效的療法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 肝病治療市場：依疾病類型分類

  • 酒精性肝臟疾病
  • B型肝炎
  • C型肝炎
  • 肝癌
    • 膽管癌
    • 肝細胞癌
  • 非酒精性肝臟疾病

第8章 肝病治療市場：依治療類型分類

  • 生物免疫療法
  • 細胞療法和再生醫學
  • 基因治療
  • 微生物組調節療法
  • 小分子藥物

第9章 肝病治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第10章 肝病治療市場：依藥物類別分類

  • 抗纖維化藥物
    • Pirfenidone
    • 辛妥珠單抗
  • 抗病毒藥物
    • 干擾素
    • NS5A抑制劑
    • NS5B聚合酵素抑制劑
    • 核苷酸/核苷類似物
    • 蛋白酶抑制劑
  • 化療藥物
  • 皮質類固醇
  • 免疫抑制劑
  • 單株抗體

第11章 肝病治療市場：依最終用戶分類

  • 診所
  • 居家醫療
  • 醫院

第12章 肝病治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 肝病治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 肝病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 肝病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genfit SA
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Intercept Pharmaceuticals, Inc.（Alfasigma SpA）
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-437A5D08AE2A

The Liver Diseases Therapeutics Market is projected to grow by USD 35.63 billion at a CAGR of 8.39% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.26 billion
Estimated Year [2026] USD 21.89 billion
Forecast Year [2032] USD 35.63 billion
CAGR (%) 8.39%

Liver diseases therapeutics is moving from symptom management toward disease modification, earlier intervention, and precision care across viral hepatitis, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), autoimmune liver disease, cholestatic disorders, cirrhosis, and hepatocellular carcinoma. The opportunity is substantial because liver disease remains a major global health burden: WHO reported 304 million people living with chronic hepatitis B or C in 2022, and viral hepatitis caused about 1.3 million deaths that year.

Demand is also being reshaped by obesity, type 2 diabetes, alcohol-related liver disease, and aging populations. MASLD is estimated to affect roughly one in three adults worldwide, creating a large pool of patients who may require noninvasive diagnostics, cardiometabolic co-management, antifibrotic treatment, and long-term monitoring. For industry leaders, progress will depend on evidence-rich pipelines, payer-ready outcomes data, scalable diagnostics, and integrated care models that connect hepatology, oncology, endocrinology, primary care, and digital health.

Transformative Shifts in the Landscape

The liver diseases therapeutics landscape is undergoing a structural shift as treatment innovation expands beyond antivirals into metabolic, immunologic, fibrotic, and oncology-driven mechanisms. Direct-acting antivirals transformed hepatitis C with cure rates commonly exceeding 95% in appropriate patients, while long-term hepatitis B strategies increasingly focus on functional cure approaches, including immune modulators, RNA-targeted therapies, and combination regimens.

In MASH, the field has entered a new era after the first U.S. FDA approval of a thyroid hormone receptor-beta agonist for adults with noncirrhotic MASH with moderate-to-advanced fibrosis. This milestone is accelerating investment in GLP-1-based metabolic therapies, FGF analogs, pan-PPAR agonists, FXR agonists, antifibrotics, and combination approaches. At the same time, liver cancer therapeutics continue to shift toward immunotherapy combinations, targeted agents, and biomarker-informed sequencing as hepatocellular carcinoma remains one of the leading causes of cancer death globally.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across liver diseases therapeutics by improving risk stratification, clinical trial design, imaging interpretation, and longitudinal disease monitoring. AI-enabled analysis of ultrasound, CT, MRI, elastography, pathology slides, laboratory patterns, and electronic health records can help identify patients with advanced fibrosis, cirrhosis decompensation risk, or hepatocellular carcinoma surveillance gaps earlier than conventional workflows.

For drug developers, AI supports target discovery, patient enrichment, synthetic control modeling, safety signal detection, and adaptive trial operations. In commercial care pathways, predictive analytics can prioritize hepatitis screening, MASLD referral, medication adherence, and transplant evaluation. The highest-value applications will be those validated across diverse populations, integrated into clinician workflows, and governed by transparent model performance, privacy protection, and regulatory-grade evidence.

Key Regional Insights

Asia-Pacific is a pivotal region for liver diseases therapeutics because of its large hepatitis B burden, rising diabetes and obesity rates, and expanding access to advanced diagnostics in China, Japan, South Korea, Australia, India, and ASEAN markets. Growth is increasingly tied to national hepatitis elimination plans, broader liver cancer surveillance, wider availability of noninvasive fibrosis testing, and local clinical trial capacity.

North America remains a leading innovation and reimbursement region, supported by specialty hepatology networks, advanced oncology care, transplant centers, and strong uptake potential for MASH therapies when supported by durable outcomes evidence. Europe benefits from structured health systems, guideline-driven screening, and established health technology assessment processes, although payer scrutiny requires robust cost-effectiveness and real-world evidence. Latin America, led by Brazil and Mexico, shows rising demand for hepatitis treatment, MASLD care, and cirrhosis management, but access variability persists across diagnostics, specialist referral, and reimbursement. The Middle East faces a dual burden of viral hepatitis and metabolic disease, with several health systems investing in prevention, diabetes management, and specialty liver care. Africa has high unmet need in hepatitis B diagnosis, birth-dose vaccination coverage, affordable antiviral access, liver cancer surveillance, and treatment infrastructure, making public health partnerships central to improved outcomes.

Key Group Insights

ASEAN markets are important for scalable hepatitis B management, hepatitis C elimination, and metabolic liver disease screening, especially as urbanization and diabetes prevalence rise across Southeast Asia. The GCC is emerging as a high-priority therapeutic environment because obesity, type 2 diabetes, and MASLD prevalence are elevated, while health systems are investing in specialty care, digital health, preventive screening, and chronic disease management programs.

The European Union is central to evidence-based reimbursement, health technology assessment, and harmonized clinical research, making real-world outcomes essential for access to MASH treatment, hepatitis therapeutics, and hepatocellular carcinoma therapy. BRICS countries combine large patient pools with expanding local manufacturing and clinical trial ecosystems, particularly in China, India, and Brazil, where hepatitis B, MASLD, and liver cancer burdens remain clinically significant. G7 markets continue to lead in specialty drug adoption, oncology innovation, precision diagnostics, and guideline-driven care pathways. NATO membership is not a healthcare market category, but many NATO countries overlap with high-income systems where liver cancer surveillance, MASH treatment, hepatitis elimination, and advanced cirrhosis care are increasingly prioritized.

Key Country Insights

The United States is a leading country for novel MASH therapeutics, hepatocellular carcinoma innovation, transplant hepatology, and high-value specialty care, while Canada emphasizes evidence-based access, public health screening, and integrated hepatitis strategies. Mexico and Brazil face growing MASLD and diabetes-related liver disease burdens, creating demand for affordable diagnostics, antiviral access, hepatology referral networks, and cirrhosis care pathways.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have mature hepatology infrastructure, strong clinical research participation, and guideline-based management of viral hepatitis, autoimmune liver disease, cholestatic disease, MASH, and liver cancer, while reimbursement decisions increasingly depend on fibrosis improvement, avoidance of decompensation, survival benefit, and quality-of-life evidence. Russia has ongoing demand for viral hepatitis and cirrhosis management, though access dynamics can vary by region and treatment category. China and India represent major clinical need due to hepatitis B, MASLD, diabetes, and liver cancer burdens, alongside expanding domestic research capacity and screening initiatives. Japan, South Korea, and Australia are advanced markets with strong surveillance systems, specialty care, noninvasive diagnostics, and readiness for precision therapeutics across chronic liver disease and hepatocellular carcinoma.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies that demonstrate measurable clinical value, including fibrosis regression, reduced progression to cirrhosis, lower decompensation risk, improved survival in liver cancer, and patient-centered quality-of-life outcomes. In MASH, success will depend on pairing pharmacotherapy with noninvasive tests, cardiometabolic management, lifestyle support, and clear treatment algorithms for primary care and hepatology referral.

Organizations should invest in inclusive clinical trials that reflect real-world comorbidities, regional genotype patterns, metabolic risk profiles, alcohol use patterns, and diverse ethnic populations. Market access teams need early health economic models that quantify avoided transplant, hospitalization, cancer, decompensation, and productivity costs. Partnerships with diagnostic developers, AI platforms, payers, public health agencies, providers, and specialty pharmacies can improve screening, adherence, surveillance, and outcomes tracking across the liver disease continuum.

Research Methodology

This executive summary is based on a structured review of publicly available evidence from authoritative sources, including WHO, CDC, EASL, AASLD, IARC, national public health agencies, peer-reviewed hepatology journals, regulatory announcements, clinical guideline updates, and clinical development disclosures. Emphasis was placed on validated epidemiology, approved therapies, late-stage pipeline trends, disease burden indicators, and care delivery patterns.

Insights were synthesized through segmentation by disease area, treatment modality, geography, health system maturity, and access environment. Claims were limited to data-backed observations and widely recognized clinical or regulatory developments, with no reliance on market sizing, market share, or forecasting. The analysis prioritizes relevant themes such as liver diseases therapeutics, MASH treatment, hepatitis B therapeutics, hepatitis C antivirals, liver fibrosis, cirrhosis management, noninvasive liver diagnostics, and hepatocellular carcinoma therapy.

Conclusion

Liver diseases therapeutics is entering a more integrated and innovation-led phase, driven by the convergence of antivirals, metabolic therapies, antifibrotics, immuno-oncology, diagnostics, and artificial intelligence. The largest opportunities will come from earlier identification of at-risk patients, improved treatment persistence, effective surveillance, and therapies that demonstrate durable clinical outcomes rather than biomarker movement alone.

For stakeholders across biopharma, diagnostics, providers, payers, and public health systems, the strategic imperative is clear: build evidence-based, scalable, and equitable liver care models. Organizations that combine strong clinical differentiation with real-world evidence, regional access strategies, and digital-enabled care pathways will be best positioned to lead the next phase of advancement in liver diseases therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Liver Diseases Therapeutics Market, by Disease Type

  • 7.1. Alcoholic Liver Disease
  • 7.2. Hepatitis B
  • 7.3. Hepatitis C
  • 7.4. Liver Cancer
    • 7.4.1. Cholangiocarcinoma
    • 7.4.2. Hepatocellular Carcinoma
  • 7.5. Non Alcoholic Lever Disease

8. Liver Diseases Therapeutics Market, by Therapy Type

  • 8.1. Biologic Immunotherapies
  • 8.2. Cell-Based & Regenerative Therapy
  • 8.3. Gene Therapy
  • 8.4. Microbiome-Modulating Therapies
  • 8.5. Small-Molecule Drugs

9. Liver Diseases Therapeutics Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Liver Diseases Therapeutics Market, by Drug Class

  • 10.1. Antifibrotic
    • 10.1.1. Pirfenidone
    • 10.1.2. Simtuzumab
  • 10.2. Antivirals
    • 10.2.1. Interferons
    • 10.2.2. NS5A Inhibitors
    • 10.2.3. NS5B Polymerase Inhibitors
    • 10.2.4. Nucleotide/Nucleoside Analogues
    • 10.2.5. Protease Inhibitors
  • 10.3. Chemotherapeutic
  • 10.4. Corticosteroids
  • 10.5. Immunosuppressants
  • 10.6. Monoclonal Antibody

11. Liver Diseases Therapeutics Market, by End User

  • 11.1. Clinic
  • 11.2. Home Care Settings
  • 11.3. Hospital

12. Liver Diseases Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Liver Diseases Therapeutics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Liver Diseases Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Liver Diseases Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Alnylam Pharmaceuticals, Inc.
  • 17.3. Astellas Pharma Inc.
  • 17.4. AstraZeneca PLC
  • 17.5. Bristol-Myers Squibb Company
  • 17.6. C. H. Boehringer Sohn AG & Co. KG
  • 17.7. Eli Lilly and Company
  • 17.8. F. Hoffmann-La Roche Ltd.
  • 17.9. Genfit S.A.
  • 17.10. Gilead Sciences, Inc.
  • 17.11. GlaxoSmithKline plc
  • 17.12. Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
  • 17.13. Johnson & Johnson Services Inc.
  • 17.14. Merck & Co., Inc.
  • 17.15. Moderna, Inc.
  • 17.16. Novartis AG
  • 17.17. Pfizer Inc.
  • 17.18. Sanofi SA
  • 17.19. Takeda Pharmaceutical Company Limited
  • 17.20. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER DISEASES THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL LIVER DISEASES THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALCOHOLIC LIVER DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ALCOHOLIC LIVER DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALCOHOLIC LIVER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEPATITIS B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEPATITIS B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEPATITIS B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEPATITIS C MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEPATITIS C MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LIVER CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVER CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LIVER CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON ALCOHOLIC LEVER DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NON ALCOHOLIC LEVER DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON ALCOHOLIC LEVER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGIC IMMUNOTHERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGIC IMMUNOTHERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGIC IMMUNOTHERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL-BASED & REGENERATIVE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL-BASED & REGENERATIVE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL-BASED & REGENERATIVE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MICROBIOME-MODULATING THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MICROBIOME-MODULATING THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MICROBIOME-MODULATING THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SMALL-MOLECULE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SMALL-MOLECULE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SMALL-MOLECULE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIFIBROTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIFIBROTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIFIBROTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PIRFENIDONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PIRFENIDONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PIRFENIDONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SIMTUZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SIMTUZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SIMTUZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTERFERONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INTERFERONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTERFERONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NS5A INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NS5A INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NS5A INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NS5B POLYMERASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NS5B POLYMERASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NS5B POLYMERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEOTIDE/NUCLEOSIDE ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEOTIDE/NUCLEOSIDE ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEOTIDE/NUCLEOSIDE ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CHEMOTHERAPEUTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHEMOTHERAPEUTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CHEMOTHERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CLINIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CLINIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CLINIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 185. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 189. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 190. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 215. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 219. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 220. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 225. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 229. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 230. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 246. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 249. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 251. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 260. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 261. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 266. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 270. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 271. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 283. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 290. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 291. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 301. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 303. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 306. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 308. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 309. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 310. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 311. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 313. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 316. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 318. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 319. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 320. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 321. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 322. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 323. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 326. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 328. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 329. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 330. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 331. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 332. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 339. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 342. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 343. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 344. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYP